GlassScriptPhysician profile
Tom Tomer Noff
NPI 1346582277
$2,533.96
in general payments reported to CMS, 2019-2025
19 companies · $1,357 in 2025
The $1,357 reported for 2025 was more than what a typical Clinical Neurophysiology provider received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.23 · 2022: $15.19 · 2023: $65.39 · 2024: $1,042 · 2025: $1,357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,429 · Education: $35.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,429.41 |
| Education | $35.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $662.67 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $430.88 | 2024 | |
| Ucb, INC. | $325.86 | 2023-2025 | Rystiggo, Zilbrysq, Briviact |
| Argenx US, INC. | $180.10 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Csl Behring | $168.84 | 2025 | Hizentra |
| Pfizer INC. | $163.31 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $158.05 | 2023-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Amgen INC. | $104.77 | 2023-2025 | Uplizna, Aimovig |
| Janssen Biotech, INC. | $86.27 | 2025 | |
| Alexion Pharmaceuticals, INC. | $79.14 | 2019-2025 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $34.08 | 2025 | Wainua |
| Alnylam Pharmaceuticals INC. | $26.95 | 2019 | |
| Springworks Therapeutics, INC. | $23.25 | 2025 | Gomekli |
| Lundbeck LLC | $16.52 | 2025 | Vyepti |
| Philips North America LLC | $15.19 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $15.13 | 2025 | Symbravo |
| Lilly USA, LLC | $15.06 | 2024 | Emgality |
| Xeris Pharmaceuticals, INC. | $14.56 | 2025 | Keveyis |
| Ipsen Biopharmaceuticals, INC | $13.33 | 2024 | Dysport |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tom Noff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.